A Study of Enzalutamide and Mifepristone in Treating Patients With Prostate Cancer
Number: NCT02012296
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1| Phase 2
Sponsor(s): University of Chicago|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Number: NCT02484404
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With and Without Ribociclib for mCRPC patients who have not received chemotherapy
Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Number: NCT02744287
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bellicum Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Number: NCT02769962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With mCRPC
Number: NCT02807805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Chong-xian Pan|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Number: NCT02861573
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Number: NCT02903160
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Icahn School of Medicine at Mount Sinai|Sanofi|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1| Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): University of California, Davis|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Number: NCT02975934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Clovis Oncology, Inc.|Foundation Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Number: NCT02985957
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With mCRPC With DNA Repair Defects
Number: NCT03012321
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|AstraZeneca|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Clinical Study of change in brain structure or activity in men treated with androgen receptor therapies such as abiraterone acetate and enzalutamide
Number: NCT03016741
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Northwestern University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Number: NCT03170960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Using Imaging for Detection of mCRPC
Number: NCT03173924
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Number: NCT03207867
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
Number: NCT03217747
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pembrolizumab in mCRPC With or Without DNA Damage Repair Defects
Number: NCT03248570
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Number: NCT03298087
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone
Number: NCT03317392
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
Number: NCT03344211
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC With Deoxyribonucleic Acid (DNA) Damage Repair Deficiencies (DDR)
Number: NCT03395197
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With mCRPC
Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Trovagene, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Niraparib Combination Therapies for the Treatment of mCRPC
Number: NCT03431350
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Number: NCT03442556
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
Number: NCT03456843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Number: NCT03460977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
Number: NCT03490838
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Advanced Accelerator Applications
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)
Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
Number: NCT03495427
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Number: NCT03549000
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of HPN424 in Patients With Advanced Prostate Cancer
Number: NCT03577028
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Number: NCT03585114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Emerson Lim|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Number: NCT03685591
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Number: NCT03706365
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03724747
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
Number: NCT03725761
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|National Cancer Institute (NCI)|Gilead Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s) |
MGC018 With or Without MGA012 in Advanced Solid Tumors
Number: NCT03729596
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03751436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Roswell Park Cancer Institute|National Cancer Institute (NCI)|AbbVie
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with MCRPC
Number: NCT03792841
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Number: NCT03799003
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Astellas Pharma Global Development, Inc.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Number: NCT03800784
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2| Phase 3
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Number: NCT03824275
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2| Phase 3
Sponsor(s): Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Number: NCT03834493
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Number: NCT03837353
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NYU Langone Health|Leap Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Number: NCT03850795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hinova Pharmaceuticals USA, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Number: NCT03866382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03888612
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arvinas Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer
Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer
Number: NCT03934840
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Masonic Cancer Center, University of Minnesota
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
Number: NCT03939689
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
Number: NCT03972657
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Number: NCT03999515
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Number: NCT04032704
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seattle Genetics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Number: NCT04060342
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.|MSD International GmbH (Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.)|Gossamer Bio Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Number: NCT04060394
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Laekna Limited
Sponsor Trial Information
Trial Location(s) and Contact(s) |
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme Corp.|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
Number: NCT04090775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rampart Health, L.L.C.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Number: NCT04100018
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Checkpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
Number: NCT04104893
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Targeting of Anti-hk2 Antibody in mCRPC
Number: NCT04116164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Tomopath Inc.|Invicro|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Number: NCT04116775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Julie Graff, MD|Merck Sharp & Dohme Corp.|Prostate Cancer Foundation|Johns Hopkins University|Oregon Health and Science University|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Number: NCT04157088
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate
Number: NCT04158245
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tulane University|Blue Earth Diagnostics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy
Number: NCT04179864
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Epizyme, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Number: NCT04207255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Number: NCT04221542
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): http://www.amgentrials.com/amgen/studysearch.aspx?SearchStr=amg+160
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients
Number: NCT04246671
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bavarian Nordic
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Number: NCT04253262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Brown University|Rhode Island Hospital|The Miriam Hospital|Bayer|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Number: NCT04267939
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Number: NCT04288687
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Abramson Cancer Center of the University of Pennsylvania
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Number: NCT04335682
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alliance Foundation Trials, LLC.|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Number: NCT04337580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Wake Forest University Health Sciences|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Number: NCT04363164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|United States Department of Defense
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Number: NCT04381832
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Number: NCT04382898
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BioNTech SE
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Number: NCT04397276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
Number: NCT04408924
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Number: NCT04446117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Exelixis|Roche-Genentech|Takeda
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy
Number: NCT04471727
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Number: NCT04471974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Zenith Epigenetics|Merck Sharp & Dohme Corp.|U.S. Army Medical Research and Development Command|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Number: NCT04495179
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca|Parexel
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic
Number: NCT04497844
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Number: NCT04503265
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): AtlasMedx, Incorporated
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Number: NCT04550494
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Number: NCT04556617
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): PlexxikonPlexxikon
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
Number: NCT04564027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Number: NCT04577833
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Number: NCT04592237
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Pharmaceutica
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Number: NCT04606446
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Number: NCT04631601
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Number: NCT04631744
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Number: NCT04644770
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Number: NCT04647526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): POINT Biopharma
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Number: NCT04666129
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Myovant Sciences GmbH
Sponsor Trial Information
Trial Location(s) and Contact(s) |
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Number: NCT04689828
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): https://ClinicalTrials.gov/show/NCT04689828
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Number: NCT04709276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew J. Armstrong, MD|Bristol-Myers Squibb|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Abemaciclib With or Without Atezolizumab for mCRPC
Number: NCT04751929
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Eli Lilly and Company|Genentech, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT04781374
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Puma Biotechnology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Number: NCT04803305
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Number: NCT04821622
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Pfizer|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Number: NCT04844749
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Veru Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Number: NCT04848337
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Ulka Vaishampayan|Merck Sharp & Dohme Corp.|University of Michigan|Hoosier Cancer Research Network
Sponsor Trial Information
Trial Location(s) and Contact(s) |
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Number: NCT04887506
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Tavanta Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Number: NCT04898634
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC
Number: NCT04946370
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University|United States Department of Defense|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Number: NCT04986423
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Zenith Epigenetics|Astellas Pharma Inc|Newsoara Biopharma Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
